Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

William Gentry

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentAnesthesiology, College of Medicine
DivisionAnesthesiology Faculty
AddressB112 Biomedical Research I
325 S. Elm St.
Mail Slot # 515
Little Rock AR 72205
Phone501-320-7601
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentPharmacology and Toxicology, College of Medicine


    Collapse Research 
    Collapse research activities and funding
    U01DA053043     (GENTRY, WILLIAM)Sep 30, 2020 - Jun 30, 2023
    NIH/Nati. Inst. on Drug Abuse - Pass Thourhg: InterveXion Therapeutics, LLC
    Meth-OD: A Phase 2A Study of IXT-m200 in Methamphetamine Overdose Patients
    Role Description: InterveXion proposes to test IXT-m200, an antibody that specifically binds methamphetamine to keep it in the blood and out of the brain, in patients who come to the emergency department with symptoms of a methamphetamine overdose, such as agitation.
    Role: Co-Principal Investigator
    U01DA051078     (GENTRY, WILLIAM)May 1, 2020 - Mar 31, 2023
    NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
    Optimization and testing of anti-methamphetamine antibody therapy to support
    Role: Principal Investigator
    U01DA045366     (GENTRY, WILLIAM)Oct 1, 2017 - Jul 31, 2021
    NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
    STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy’
    Role: Principal Investigator
    U01DA035511     (OWENS, SAMUEL)Jun 1, 2017 - May 31, 2019
    NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
    A Methamphetamine Conjugate Vaccine: From Manufacturing to IND - Continuation - Continuation
    Role: Co-Investigator
    U01DA037593     (GENTRY, WILLIAM)Sep 15, 2014 - Jun 30, 2018
    NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
    Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb
    Role: Principal Investigator
    R21DA031837     (OLIVETO, ALISON)May 1, 2012 - Aug 31, 2015
    NIH/Nat. Inst. on Drug Abuse
    Impact of CYP2D6 Phenotype on Response to Methamphetamine in Humans
    Role: Co-Investigator
    R01DA031944     (GENTRY, WILLIAM)Jul 15, 2011 - Jun 30, 2015
    NIH/Nat. Inst. on Drug Abuse
    First Human Studies of a Chimeric Anti-Methamphetamine Monoclonal Antibody
    Role: Principal Investigator
    RC2DA028915     (GENTRY, WILLIAM)Oct 1, 2009 - Aug 20, 2012
    NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
    Chimeric anti-Methamphetamine Monoclonal Antibody for Treatment of METH Toxicity
    Role: Principal Investigator
    R01DA026916     (GENTRY, WILLIAM)Sep 1, 2009 - Jul 31, 2013
    NIH/Nat. Inst. on Drug Abuse
    Monoamine Antagonist Therapies for Methamphetamine Abuse
    Role: Principal Investigator
    U01DA023900     (OWENS, SAMUEL)Sep 30, 2007 - Aug 31, 2013
    NIH/Nat. Inst. on Drug Abuse
    Active Immunization for Treating Methamphetamine Abuse
    Role: Co-Investigator
    R42DA017596     (GENTRY, WILLIAM)Jul 1, 2006 - Oct 31, 2010
    NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
    Development of Plant Derived Antibodies for Drug Abuse
    Role: Principal Investigator
    K08DA00339     (GENTRY, WILLIAM)May 1, 2002 - Apr 30, 2004
    NIH/Nat. Inst. on Drug Abuse
    Mechanisms of Onset & Offset of Rapid Stimulant Effects
    Role: Principal Investigator
    R01DA011560     (OWENS, SAMUEL)Jan 5, 1998 - Mar 31, 2012
    NIH/Nat. Inst. on Drug Abuse
    Antibody-based Therapy for Methamphetamine Abuse
    Role: Co-Investigator
    R01DA010017     (OLIVETO, ALISON)Sep 30, 1997 - Nov 30, 2012
    NIH
    Opioid Antagonist Discrimination: A Model of Withdrawal
    Role: Co-Investigator
    R01DA007610     (OWENS, SAMUEL)Mar 1, 1992 - Jun 30, 2012
    NIH/Nat. Inst. on Drug Abuse
    Immunotherapy for Drug Abuse
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Hum Vaccin Immunother. 2014; 10(9):2638-47. PMID: 25483484.
      View in: PubMed
    2. White SJ, Hendrickson HP, Atchley WT, Laurenzana EM, Gentry WB, Williams DK, Owens SM. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. Drug Metab Dispos. 2014 Aug; 42(8):1285-91. PMID: 24839971.
      View in: PubMed
    3. Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs. 2014; 6(6):1649-56. PMID: 25484042.
      View in: PubMed
    4. Oliveto A, Mancino M, Sanders N, Cargile C, Guise JB, Bickel W, Gentry W Brooks. Effects of Prototypic Calcium Channel Blockers in Methadone-Maintained Humans Under a Naloxone Discrimination Procedure. Eur J Pharmacol. 2013.
    5. Walker BL, Vander Schilden JL, Gentry W Brooks. Intraarticular Analgesia Using a Meperidine-Local Anesthetic Combination in Arthroscopic Knee Procedures. Chirurgia Kolana, Atroskopia, Traumatologia Sportowa. 2013; 8(1):21-27.
    6. White SJ, Laurenzana EM, Hendrickson HP, Gentry WB, Owens SM. Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine and (+)-amphetamine in rats. Drug Metab Disp. 2011; 39:1718-26.
    7. Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. The Fate and Function of Therapeutic Anti-addiction Monoclonal Antibodies. J Pharmacol Exp Ther. 2011; 336:414-22.
    8. Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J. Behavioral Effects of Gamma-Hydroxybutyrate (GHB) in Humans. Behavioral Pharmacology. 2010; 21:332-342.
    9. White SJ, Laurenzana EM, Gentry WB, Hendrickson HP, Williams DK, Ward KW, Owens SM. Vulnerability to (+)-methamphetamine effects and the relationship to drug disposition in pregnant rats during chronic infusion. Toxicol Sci. 2009 Sep; 111(1):27-36. PMID: 19520673.
      View in: PubMed
    10. Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-PCP Monoclonal Antibody Binding Capacity is not the Only Determinant of Effectiveness, Disproving the Concept that Antibody Capacity is easily Surmounted. Drug Metab Dispos. 2006; 34:906-912.
    11. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S. Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A4 Activity: Comparison of Milk Thistle and Black Cohosh to rifampin and Clarithromycin. J Clin Pharmacol. 2006; 46:201-213.
    12. Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and Efficiency of an Anti-(+)-Methamphetamine Monoclonal IgG in the Protection against Cardiovascular and Central Nervous System Effects of (+)-Methamphetamine in Rats. International Immunopharmacology. 2006; 6:968-977.
    Gentry's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (40) concept(s)
    _
    Co-Authors Expand Description
    See all (1) people
    _
    Similar People Expand Description
    See all (25) people
    _
    Same Department Expand Description
    Search Department